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Background: Ovarian cancer is now recognized as a number of distinct diseases primarily defined by histological
subtype. Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from
endometriosis and frequently harbor mutations in the ARID1A tumor suppressor gene. We studied the influence of
histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes
associated with ARID1A mutation/BAF250a expression in EC and CCC.
Methods: Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive
ovarian carcinomas (33 CCC, 29 EC, and 65 high-grade serous ovarian carcinomas (HGSC)). Whole tumor
lysates were prepared from frozen banked tumor samples and profiled by RPPA using 116 antibodies. ARID1A
mutations were identified by exome sequencing, and PIK3CA mutations were characterized by MALDI-TOF mass
spectrometry. SAM (Significance Analysis of Microarrays) was performed to determine differential protein
expression by histological subtype and ARID1A mutation status. Multivariate logistic regression was used to
assess the impact of ARID1A mutation status/BAF250a expression on AKT phosphorylation (pAKT). PIK3CA
mutation type and PTEN expression were included in the model. BAF250a knockdown was performed in 3 clear
cell lines using siRNA to ARID1A.
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Results: Marked differences in protein expression were observed that are driven by histotype. Compared to
HGSC, SAM identified over 50 proteins that are differentially expressed in CCC and EC. These included PI3K/AKT
pathway proteins, those regulating the cell cycle, apoptosis, transcription, and other signaling pathways
including steroid hormone signaling. Multivariate models showed that tumors with loss of BAF250a expression
showed significantly higher levels of AKT-Thr308 and AKT-Ser473 phosphorylation (p < 0.05). In 31 CCC cases, pAKT
was similarly significantly increased in tumors with BAF250a loss on IHC. Knockdown of BAF250a by siRNA in
three CCC cell lines wild type for ARID1A showed no increase in either pAKT-Thr308 or pAKT-S473 suggesting that
pAKT in tumor tissues is indirectly regulated by BAF250a expression.
Conclusions: Proteomic assessment of CCC and EC demonstrates remarkable differences in protein expression that
are dependent on histotype, thereby further characterizing these cancers. AKT phosphorylation is associated with
ARID1A/BAF250a deficient tumors, however in ovarian cancers the mechanism remains to be elucidated.
Keywords: Ovarian cancer, Proteomics, ARID1A/BAF250a, PIK3CA mutation, AKT, PhosphorylationBackground
There are important clinical and molecular differences
between histological subtypes of ovarian cancer [1,2]. High-
grade serous carcinoma (HGSC) is the most common sub-
type of ovarian cancer representing approximately 70% of
cases, whereas clear cell carcinoma (CCC) and endome-
trioid carcinoma (EC) are less common, occurring at a fre-
quency of approximately 12% and 11% respectively [3].
Whereas HGSC frequently originates from precursor le-
sions in the fallopian tube [4,5], both CCC and EC may
arise from endometriosis and are associated with a younger
age of onset [6-10]. Compared to HGSC, both CCC and
EC present with earlier-stage disease, and CCC are less sen-
sitive to common chemotherapy regimens used to treat
ovarian cancers [11]. Approximately 50% of CCC and 30%
of EC harbor mutations in the chromatin-remodeling gene
ARID1A [12,13]. ARID1A functions as a tumor suppressor
gene [14], although there are no proven clinical features or
differences in outcomes associated with a reduction or loss
of expression of its associated protein (BAF250a) by immu-
nohistochemistry (IHC) [12,15].
PIK3CA mutations are common in ovarian CCC, endo-
metrial and breast cancers [16-19] and they are frequently
co-mutated with ARID1A in ovarian CCC [13]. The impact
of these co-mutations on phosphorylation of AKT has been
studied in endometrial cancers and it was found that tu-
mors with mutated ARID1A were associated with increased
AKT phosphorylation and pathway activation [20]. In this
same study, PTEN mutations were also significantly associ-
ated with mutations in ARID1A. Further research is needed
in order to determine whether these observations in endo-
metrial cancer also pertain to ovarian CCC and EC. There-
fore, the purpose of this study was to examine protein
expression in ovarian EC and CCC using RPPA and to de-
termine whether expression patterns are specific to histo-
type. We also sought to determine proteomic patterns of
expression based on ARID1A mutation status/BAF250a
protein expression in ovarian EC and CCC, and furtherstudy the impact of mutation status (ARID1A and PIK3CA)
and PTEN expression on AKT phosphorylation.
Methods
Reverse phase protein array
We performed RPPA on whole tumor lysates as previously
described [21,22]. RPPA is suited for functional proteomic
assessments of a large number of tumor samples and pro-
vides a platform for comparing the relative protein expres-
sion between these samples. Using RPPA, 116 antibodies
were utilized to assay protein expression of cell surface
growth factor receptors, common signaling pathway pro-
teins, steroid hormone receptors, and others proteins in-
volved in proliferation and apoptosis. RPPA provides an
estimate of the relative protein expression of each sample
in relation to the other samples on the slide. A list of anti-
bodies used for RPPA is included as Additional file 1:
Table S1.
Collection of tumor samples and IHC
Tumor samples (n = 127) were obtained from the gyneco-
logic tumor bank at Vancouver General Hospital and
the British Columbia Cancer Agency. The research was
conducted with approval from the University of British
Columbia institutional review board. Tumor samples were
collected at the time of primary surgery and snap frozen
within 60 minutes after collection. Patients treated by neo-
adjuvant chemotherapy were excluded from the study. All
patient samples were subjected to pathology review (BG)
to confirm the histological subtype and site of origin. Clin-
ical data was accessed through the Cheryl Brown Ovarian
Cancer Outcomes Unit and is updated on a regular basis.
Tumors were studied by IHC as part of a tumor bank tis-
sue microarray (TMA). Methods for preparation, staining,
and scoring of the EOC cases for BAF250a have been pre-
viously described [12]; tumors with any degree of nuclear
staining for BAF250a protein expression considered a
positive score for purposes of this study.
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Cell line identities were verified with short tandem repeat
(STR) DNA identity testing with the AmpFLSTR® Identifi-
ler® Direct PCR Amplification Kit as per the manufac-
turer’s protocol (Applied Biosystems®, Life Technologies
Corp.) ES2 was obtained from the American Type Culture
Collection (ATCC); STR typing to confirm the cell line
identity was performed May 12, 2011 and verified against
the ATCC STR database. JHOC-5 was obtained from the
RIKEN cell bank; STR typing was performed on April 18,
2011 and verified against the RIKEN DSMZ STR Profiler.
RMG-1 was obtained from the Health Sciences Research
Resources Bank (HSRRB) cell bank; short tandem repeat
(STR) DNA identity testing was performed on April 18,
2011 and verified against the HSRRB STR database. Cells
were cultured in RPMI with 5-10% FBS, with the excep-
tion of the ES-2 cells, which were grown in McCoy’s
media. Cells were treated with pooled siRNA (Dharmacon)
to ARID1A at 20 nM using RNAiMax™ as a transfection
reagent (Invitrogen) according to the manufacturer’s re-
commended protocol. Lysates were prepared 60 hours
following transfection using Bicine/CHAPS lysis buffer
(20 mM Bicine/0.6% CHAPS, pH 7.6). EGF stimulation
was performed using 20 ng/ml EGF for 15–20 minutes as
a positive control. Protein levels were assessed by Western
blotting (SDS-PAGE). Antibodies used were as follows:
BAF250a (Sigma- HPA005456), AKTp473 (Cell Signaling
9271, AKTp308 (Cell Signaling 9275), PDK1 (Cell Signal-
ing 3062), p70S6 Kinase (Santa Cruz sc-8418), PTEN (Cell
Signaling 9552), and β-actin (Cell Signaling 3700).
Isoelectric focusing for AKT protein expression
Native capillary isoelectric point focusing was used to as-
sess AKT expression according to recommended proto-
cols using NanoPro™ 2000 (ProteinSimple™, Santa Clara,
CA) [23]. G2 premix (pH 5–8) was used for all experi-
ments (ProteinSimple™, # 040–972) Primary antibodies in-
cluded AKT1 antibody (Santa Cruz, (C-20): sc1618), and
ERK 1/2 (ProteinSimple™, Catalog #040-474). Secondary
antibodies used were bovine anti-goat (Jackson Labs, Cat#
805-035-180), and goat anti-rabbit (Sigma, #A0545).
DNA sequencing of tumors and mutational analyses
The ARID1A mutations were determined primarily by
exome sequencing using next generation technologies
and these results were previously described by our group
[12]. Common oncogenic mutations were determined by
MALDI-TOF mass spectrometry (MassARRAY®, Seque-
nom Inc.) of primer extension polymerase chain reaction
(PCR) products [24]. Mutations of PIK3CA were catego-
rized as kinase domain mutation H1047R, and helical
domain mutations (E542K, E545K, and also E545D and
Q546R). In addition, there were several other less com-
mon mutations included (N345K, R88Q, E110K).Statistical methods
To assess tumor protein expression unsupervised and su-
pervised cluster analysis was performed using TreeView
software (University of Glasgow, Scotland). X-cluster was
used to generate heat maps and cluster groups (Stanford).
Data was analyzed using SPSS software (Version 20,
Chicago, Illinois). Proteins that were differentially expressed
in CCC relative to the other subtypes were determined by
t-testing and significance analysis of microarray data (SAM)
[25]. SAM was used to determine the probability that dif-
ferences in expression within each group studied are due to
false discovery. False discovery rates (FDR) of less 5% were
considered significant. Median protein expression levels
were used as cut-points for multivariate logistic regression
models except for PTEN expression. A cut-point of the
lowest 20% of values on RPPA was chosen for PTEN loss
based on previous work showing a 28% incidence of PTEN
loss in CCC [26], and IHC data from our own center show-
ing a 12% incidence of PTEN loss in 42 cases of CCC/EC.
Results
EOC protein expression is histotype specific
127 ovarian cancers were submitted for RPPA: 33 CCC, 29
EC, and 65 HGSC. Hierarchical clustering of treatment-
naïve samples and proteins analyzed by RPPA is shown
in Figure 1. It is evident that clustering is driven by
histological subtype; CCC and EC form distinct clusters
separated by two major HGSC subgroups. Differential ex-
pression of proteins was examined by significance analysis
of microarray data (SAM) for both CCC and EC com-
pared to HGSC as the reference group. Figure 2 shows the
differentially expressed proteins according to histological
subtype. Interestingly a number of proteins are down-
regulated in both EC and CCC relative to the HGS group.
Notable proteins are GAB2, YAP, Cyclin B1, CofilinpSer3,
and Caveolin1, 4EBP1pThr37, STAT5, and c-Myc. CCC
have lower ERα, AR, and PR expression compared to
HGSC. The complete list of protein comparisons by SAM
and histotype is included as Additional file 2: Table S2.
Other proteins with low expression in CCC include β-
Catenin, fibronectin, PTEN, 4EBP1, and stathmin. EC are
characterized by lower levels of Cyclin E1, phosphorylated
S6, 14-3-3 Zeta, BIM, and STAT3.
CCC and EC shared four proteins that were up-regulated
compared to HGSC. Notably pAKT-Thr308 is higher in
both histologies though pAKT-Ser473 was of borderline sig-
nificance. (FDR = 5.2 and 6.9 respectively). Other up-
regulated proteins in both CCC and EC include p21,
HSP70, and 4EBP1-pSer65. EC as expected have higher ex-
pression of ERα, ERαpSer118 and PR compared to HGSC,
while IRS1, CHK1, EGFR, and Cyclin D1 were also ele-
vated. Some of the up-regulated proteins that characterize
CCC include α-Catenin, Cyclin E1, HSP27, E-cadherin,
p38, p38pThr180Tyr182, SMAD3, and GSK proteins.
Figure 1 Hierarchical clustering of samples and proteins analyzed by RPPA. CCC and ECs form distinct clusters separated by two major
high-grade serous carcinoma (HGSC) subgroups. Differential expression of proteins was examined by significance analysis of microarray data
(SAM analysis) for both CCC and EC compared to HGSC as the reference group.
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ated with BAF250a IHC score by SAM in the 31 CCC with
known ARID1A mutation status. There were only 2 cases
of EC with negative BAF250a IHC so the EC were not in-
cluded in this analysis. The only differentially expressed
protein with a low false discovery rate (FDR) was pAKT-
Thr308 (FDR < 1%). The top 4 other proteins differentially
expressed were as follows: Bcl-2, p27, phosphorylated p38,
and pAKT-Ser473. FDR rates by SAM for these 5 proteins
varied from 16-20%. AKT phosphorylation levels were
higher in BAF250a IHC negative tumors while the other 3
proteins had lower levels.Investigating the effect of BAF250a/ARID1A and PIK3CA
mutation on protein expression
We examined the effect of ARID1A mutation/BAF250a
loss on changes in protein expression in the CCC and
EC tumors with known ARID1A mutation status,
BAF250a expression by IHC, and PIK3CA mutation
status. Table 1 shows the characteristics of this study
population. Complete sequencing data for ARID1A and
PIK3CA mutation status, and BAF250a expression by
IHC were available on 90 of the 127 original cases
used for proteomic analysis. ARID1A mutations were
present in 17 of 31 CCC in this study (55%), and 5 of
Figure 2 SAM Analysis of differentially expressed proteins by histotype: A. Upregulated and B. Down-regulated Proteins in Clear Cell and
Endometrioid Carcinoma by SAM analysis on RPPA data, with High Grade Serous Carcinoma (HGSC) as the reference group. Proteins with FDR* of
<5% are shown. Proteins that are over or under expressed in both CCC and EC are shown in the center between the two subtypes. Note: *FDR
(False discovery rate): For each analysis (e.g. CCC vs. EC), the percent probability that the difference in protein expression for each comparison is
attributable to chance after correcting for multiple parameter testing.
Table 1 Patient/sample characteristics with known
ARID1A mutation status according to histotype
Clear cell Endometrioid Serous
Characteristic No. (%) No. (%) No. (%)
Stage
1/2 19 (61) 21 (88) 6 (17)
3/4 11 (35) 2 (8) 29 (83)
Missing 1 (3) 1 (3)
ARID1A mutation
No 14 (45) 19 (79) 35 (100)
Yes 17 (55) 5 (21) 0 (0)
PIK3CA mutation
None 17 (55) 13 (54) NT
Helical 7 (23) 4 (17) NT
Kinase 4 (13) 4 (17) NT
Other 3 (9) 3 (12) NT
NT = not tested.
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showed PIK3CA mutations in 45% of CCC and 46% of
EC. Mutations of PIK3CA were categorized as kinase
domain (H1047R), helical domain (E542K, E545K,
E545D and Q546R), or other (less common) including
(N345K, R88Q, and E110K). Fifty-seven percent of
tumors (13/23) with ARID1A mutations had PIK3CA
mutations versus 38% (12/32) percent of tumors
wild type for ARID1A (p = 0.3; Chi-square test). Since
previous reports have shown that PIK3CA mutations
have differing effects on PIK3CA signaling and AKT
phosphorylation, we investigated the role of different
PIK3CA mutations in relation to ARID1A mutation or
loss by IHC. While 8/11 (73%) PIK3CA helical domain
mutants were wild type for ARID1A; kinase/other
domain mutants were more common in tumors with
ARID1A mutations (10/14; 71%), (p = 0.05; Fisher’s
exact test). Figure 3 shows a heat map with samples
categorized according to BAF250a IHC result and
PIK3CA mutation status. It is evident there are no
obvious clustering patterns due either BAF250a or
PIK3CA mutation status.
Figure 3 Heat map with samples categorized according to BAF250a IHC scores and PIK3CA mutation status. No obvious clustering
patterns due to either BAF250a by IHC or PIK3CA mutation status are present. Note: capital letters for each sample histotype label (eg. CCC)
indicates expression of BAF250a on IHC, small letters (e.g. ccc) indicates loss of BAF250a expression. For PIK3CA mutations, a + sign after the
sample label (e.g. CCC+) indicates the presence of a PIK3CA mutation (either helical, kinase, or other) whereas a – sign indicates no mutation.
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PIK3CAmutations (particularly in tumors without PTEN loss)
are associated with elevated pAKT
Table 2 shows the uni- and multivariate analyses of AKT
phosphorylation based on ARID1A mutation status, BAF250a
IHC expression, PIK3CA mutation status, and PTEN levels
by RPPA. On univariate testing, pAKT-Thr308 expression by
RPPA was significantly higher in tumors that were BAF250a
negative by IHC (p = 0.007), and those with low PTEN
(p= 0.025). In contrast, neither ARID1A mutation status nor
the presence of a PIK3CA mutation was associated with a
change in pAKT-Thr308 levels. Changes in pAKT-Ser473 were
not associated with any of the above factors on univariate
testing.
In terms of clarifying the impact of the different PIK3CA
mutations on pAKT, the distributions (box plots) of pAKT-
Thr308 and pAKT-Ser473 were compared (Additional file 3:
Figure S1). By ANOVA, mutation status was not associated
with significantly different pAKT levels by RPPA. Helical do-
main mutants were not associated with an increase in pAKT
levels whereas kinase domain and other mutants resulted in
slightly higher mean levels of pAKT (both Thr308 and Ser473)
that were not statistically significant. Loss of PTEN is anotherknown mechanism for activation of PI3K pathway signaling.
When the eleven low PTEN cases were excluded, kinase
domain and other less common mutants had significantly
higher pAKT-Thr308 (p < 0.05; t-test Bonferroni corrected)
than wild type, while helical domain mutants did not. For
pAKT-Ser473, only the uncommon mutants had significantly
higher levels by RPPA (p < 0.05; t-test Bonferroni corrected)
compared to wild type or helical domain mutants.
Multivariate logistic regression showed that pAKT-Thr308
levels by RPPA are significantly higher in tumors with loss
of BAF250a expression (p = 0.002), those with low PTEN
(p = 0.003), and cancers with activating PIK3CA mutations
(p = 0.02). As with the univariate testing, pAKT-Thr308
levels were not associated with ARID1A mutation status.
On multivariate analysis, increases in pAKT-Ser473 were
only associated with BAF250a expression levels (p = 0.04).
Subgroup analysis of AKT phosphorylation in tumors
without PIK3CA mutations (18 CCC and 12 EC) showed
statistically significant increases in both pAKT-Ser473 and
pAKT-Thr308 for 8 cancers lacking BAF250a expression
on IHC (p = 0.05 and 0.008 respectively; t-test). Multivari-
ate logistic regression analysis on only the 31 clear cell
cancers with known ARID1A mutation status showed both
Table 2 Effect of PIK3CA mutations, ARID1A mutations, and BAF250a Expression on Akt phosphorylation
Test variable N Univariate testing Multivariate testing
Mean (SD) Ioge odds ratio/p-value
pAKT-Thr308 pAKT-Ser473 pAKT-Thr308 pAKT-Ser473
ARID1A mutation
Yes 22 0.31 (0.64) 0.24 (0.78) 0.41 2.4
No 33 0.06 (0.72) 0.0 (0.86) p = 0.36 p = 0.17
BAF250a expression
Yes 43 0.03 (0.67) 0.0 (0.82) 0.03 0.21
No 12 0.63 (0.60)* 0.41 (0.83) p = 0.002* p = 0.04*
PIK3CA mutation
Helical 11 0.11 (0.81) - 0.25 (0.88) 2.2 1.3
Kinase 8 0.50 (0.28) 0.27 (0.39) p = 0.02* p = 0.39
Other 6 0.39 (0.82) 0.50 (0.98)
None 30 0.05 (0.69) 0.09 (0.86)
PTEN level
PTEN low§ 11 0.78 (0.97)* 0.57 (1.3) 0.1 0.24
PTEN Normal 44 0.01 (0.51) - 0.03 (0.65) p = 0.01* p = 0.07
Note: univariate mean and standard deviation values represent Iog2 relative protein expression measured by RPPA.
*significant p-value (< 0.05).
§lowest 20% of samples by RPPA.
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in tumors with BAF250a loss by IHC (p = 0.05 and 0.005
respectively). The EC subgroup was not similarly analyzed,
as there were too few ARID1A mutant/BAF250a negative
cases for comparison.siRNA knockdown of BAF250a does not effect AKT
phosphorylation in CCC cell lines
In the BAF250a-expressing cell lines RMG1, JHOC5 and
ES2, despite good knockdown of BAF250a, changes in
AKT phosphorylation (pAKT) or p70S6K, a downstream
signaling protein of pAKT were not observed in any of the
cell lines tested (Figure 4). Although pAKT-Thr308 was
difficult to detect in the RMG1 cell lines, with EGF stimula-
tion all cell lines showed an increase in pAKT except
for pAKT-Ser473 in the JHOC5 cells, however changes in
pAKT were not altered by BAF250a knockdown. We also
observed that PDK1, PTEN levels did not change with
BAF250a knockdown in any of the cell lines. Native protein
AKT profiles assessed using capillary tube isoelectric point
focusing (Figure 4B-D) are sensitive to phosphorylation
events [27]. AKT profiles using this technology confirmed
western blot results with no change in AKT profiles in two
of the cells lines (RMG1 and JHOC5) and possibly a very
slight increase in pAKT (isoforms 1 and 2 for the ES2 cell
line). Taken together, these findings indicate that BAF250a
knockdown has little to no effect in AKT phosphorylation
in the cell lines tested.Clinical outcomes
Due to the limited cohort size, survival outcomes were not
examined. Instead, FIGO stage distribution at presentation
was analyzed to determine if this was influenced by
BAF250a loss, PIK3CA, or ARID1Amutation status. For this
comparison, FIGO stage was classified as low-stage (stage
1/2) or advanced-stage (stage 3/4). Those patients with
BAF250a loss were more likely to have advanced stage
(5/11 = 45% vs. 9/42 = 21%), however this difference was not
statistically significant (p = 0.13). Eighty-four percent (21/25)
of patients with a PIK3CA mutation presented with low-
stage disease, compared to 64% (18/28; 2 cases with miss-
ing stage) without a mutation. Again, this difference was
not statistically significant (p = 0.13). Changes in AKT
phosphorylation were also not associated with stage.Discussion
We used functional proteomics Reverse Phase Protein Array
(RPPA) to assess differential protein expression in CCC and
EC compared to HGSC. RPPA has been validated as a
means of outcome prediction in breast and ovarian cancers
[28,29], and is therefore a useful technology. It is apparent
that protein expression is clearly related to histotype, as has
been previously shown both by IHC classification and RPPA
[1,30]. As expected EC has higher levels of steroid hormone
receptor expression (AR, PR) while CCC has lower expres-
sion (AR, ER, PR) relative to HGSC. Figure 2 shows that
here are more than 50 differentially expressed proteins that
Figure 4 A) Western blot results from siRNA knockdown of BAF250a on cell lines ES2, JHOC5, and RMG1 to clarify the interaction between
BAF250a expression and pAKT. Despite good knockdown of BAF250a no change in AKT phosphorylation or levels of p70S6K, a downstream
signaling protein of pAKT can be seen in the ES2 and RMG1 cell lines. The baseline levels of pAKT are much higher in the JHOC5 cell line, and there is
a suggestion of an increase in pAKT-Thr308 with BAF250a knockdown without obvious similar changes in pAKT-Ser473. PDK1 and PTEN levels did not
change with BAF250a knockdown in any of the cell lines. B-D) Native protein AKT profiles using capillary tube isoelectric point focusing. Native AKT
profiles are consistent with the western blot result in A, as little change occurs in AKT/pAKT following siRNA mediated BAF250a knockdown.
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note that our study is descriptive with respect to these pro-
tein associations, as they have not been validated by other
means.
This study provides evidence that BAF250a expression
identifies a subgroup of CCC and EC with higher AKT-
Thr308 and AKT-Ser473 phosphorylation. Based on RPPA
expression levels, tumors lacking BAF250a by IHC show
higher levels of AKT phosphorylation independent of
PIK3CA mutation and PTEN loss. Similarly in the cohort
of CCC, multivariate analysis showed that increased pAKT
(pAKT-Thr308 and pAKT-Ser473) was associated with
BAF250a expression loss. As previously shown in endomet-
rial cancers, increased pAKT was also found in tumors with
ARID1A/BAF250a loss when both PIK3CA mutation or
PTEN loss were absent [20].
We previously reported that ARID1A mutation status
correlates with BAF250a loss by IHC [12]. In this previousreport 73% of CCC with an ARID1A mutation showed
BAF250a loss by IHC, while the correlation was less (50%)
in EC. This current study contained a subset of cases from
the original report, and found that loss of BAF250a pro-
tein by IHC showed a stronger association with pAKT
changes than actual ARID1A mutation status. Thus, the
assessment of BAF250a by IHC may be preferable to se-
quencing ARID1A in tumor samples to identify associa-
tions with AKT signaling. Mutations in ARID1A are often
heterozygous [13] and in such cases it is unknown to what
extent BAF250a expression/function is impaired and
therefore still detectable by IHC. This could also be true
for some somatic mutations. Conversely, IHC can detect
epigenetic loss of function events such as methylation that
may be as biologically deleterious as homozygous non-
sense mutations. These same considerations have previ-
ously been described in relation to PTEN assessment. IHC
appears to be preferable to sequencing for assessment of
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greater proportion of cases (44%) show PTEN loss by IHC
in the presence of a normal PTEN sequence [31]. Further
research should be done to confirm the findings of this
study and as our sample size is limited due to the fact that
CCC and EC are relatively uncommon.
Unlike previously reported observations in endometrial
cancers cell lines [20], we have been unable to demonstrate
a mechanism by which AKT phosphorylation (pAKT) oc-
curs in tumors using cell line models (RMG1, ES2, and
JHOC5). Despite good knockdown of BAF250a in these
lines, we could not demonstrate clear increases in pAKT,
or downstream signaling. Our findings suggest cell line
models may not accurately reflect the signaling changes in
tumor samples. Other possible explanations include pAKT
modulation by tumor/stromal interactions, cell lineage spe-
cificity, or the association of pAKT with other mutations
such as PIK3CA regulatory domain mutations as they have
also been shown to alter pAKT [31].
PIK3CA mutations are frequent in EC and CCC, as well
as endometrial and breast cancers [16-19]. There is evi-
dence indicating different PIK3CA mutations have differing
effects on PIK3CA signaling and AKT phosphorylation,
and therefore may determine prognosis. In breast cancer
patients, a recent study suggests patients with PIK3CA mu-
tations may actually have a more favorable prognosis [32],
and that tumors with PIK3CA mutations irrespective of
cancer type might have improved response rates to PI3K-
directed therapies. In cell lines, helical domain mutants are
not consistently associated with increases in pAKT and
appear to act through alternate signaling mechanisms po-
tentially involving SGK3 [33]. Similarly, we were not able to
identify obvious increases in pAKT signaling in EOC pa-
tients with helical domain PIK3CA mutants.
This study provides important insights relating to protein
expression particularly in ovarian CCC and EC. Because
CCC and EC are relatively uncommon compared to high
grade serous ovarian cancer (HGSC), it is difficult to gather
large numbers of patient samples in order to have the
power to detect multiple pathway aberrations. We were un-
able to show downstream pathway effects resulting from
pAKT. Furthermore, selection and validation of antibodies
for RPPA may potentially bias results so further study of a
larger population of patients is important to confirm and
clarify the associations we have found between AKT phos-
phorylation and BAF250a loss. The identification of down-
stream signaling aberrations also provides supporting
evidence of the biological significance of pAKT. It will be
helpful in future studies to also screen for other mutations
such as regulatory domain mutations of PIK3CA as it may
be that ARID1A loss is simply associated with other cellular
events that increase pAKT rather than being a direct cause.
It is interesting to note that aside from pAKT, prote-
omic aberrations resulting from ARID1A/BAF250a lossin this study are otherwise absent. This finding supports
clinical observations to date those patients with ARID1A
mutant ovarian clear cell endometrial carcinomas do not
have a phenotype associated with differing outcomes or
treatment responses [12,15,34]. Recently however a report
in patients with bladder cancer found that ARID1A/
BAF250a deficient tumors are associated with a more ag-
gressive phenotype [35]. These findings do not negate the
importance of studying signaling pathway aberrations as
this information may lead to finding new therapeutic tar-
gets. Furthermore, much work is being done to better
understand the mechanism of action of novel AKT/PI3K
directed therapies [36]. CCC is less sensitive to chemother-
apy [37] and the addition of other chemotherapy agents
such as irinotecan has been disappointing [38]. While histo-
type designation is key to classifying ovarian cancers, more
research is also needed to find markers that identify patient
subgroups who will benefit from novel therapies.
Conclusions
Using functional proteomics this study identified over 50
proteins that are differentially expressed when CCC and EC
are compared to HGSC. Interestingly, functional protein
aberrations resulting from the common occurrence of
ARID1A mutation/BAF250a loss are limited. Only increases
in AKT phosphorylation were found to be associated with
BAF250a loss though our ability to detect changes in other
PI3K pathway proteins may be limited based on sample
size. Knockdown experiments in clear cell cancer lines
failed to show a direct effect on AKT phosphorylation sug-
gesting an indirect/alternative mechanism for AKT phos-
phorylation in CCC. Further study is needed to determine
the mechanism for the association between BAF250a loss
and pAKT in CCC and EC, and explore the diagnostic and
therapeutic implications of the described changes in protein
expression relating to histotype.
Note: For full protein names see antibody list (Additional
file 1: Table S1).Additional files
Additional file 1: Table S1. Antibody list.
Additional file 2: Table S2. SAM Data.
Additional file 3: Figure S1. Box plots of pAKT levels according to
PIK3CA Mutation Status.Abbreviations
ATCC: American type culture collection; CCC: Ovarian clear cell carcinoma;
EC: Ovarian endometrioid carcinoma; FDR: False discovery rate;
HSRRB: Health sciences research resources bank; HGSC: High-grade serous
ovarian cancer; IHC: Immunohistochemistry; MALDI-TOF MS: Matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry; pAKT: AKT
phosphorylation; PCR: Polymerase chain reaction; RPPA: Reverse phase
protein array; SAM: Significance analysis of microarrays; siRNA: Small
interfering RNA; STR: Short tandem repeat; TMA: Tissue microarray.
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